Iovance Biotherapeutics, Inc.
IOVA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001425205
No open-market purchases or sales by Iovance Biotherapeutics, Inc. insiders were filed in the last 90 days; 293 institutions reported holding it in 13F filings for Q2 2026, worth $1.19B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:48 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $391.0M (148.4% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 27, 2025 | Feb 20, 2024 | Feb 28, 2023 | Feb 24, 2022 |
| Revenue | $263.5M | $164.1M | $1.19M | – | – |
| Cost of revenue | $173.2M | $124.0M | $10.8M | – | – |
| Operating expenses | – | – | – | $398.9M | $342.7M |
| Research and development | $300.3M | $282.3M | $344.1M | $294.8M | $259.0M |
| Selling, general and administrative | $152.3M | $153.0M | $106.9M | $104.1M | $83.7M |
| Operating income | -$403.4M | -$395.3M | -$460.6M | -$398.9M | -$342.7M |
| Income tax | -$2.07M | -$2.83M | -$3.48M | – | – |
| Net income | -$391.0M | -$372.2M | -$444.0M | -$395.9M | -$342.3M |
| EPS, basic | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 |
| EPS, diluted | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 |
| Weighted shares, basic | 357.3K | 289.9K | 235.1K | 159.3K | 153.4K |
| Weighted shares, diluted | 357.3K | 289.9K | 235.1K | 159.3K | 153.4K |
| Margins and growth | |||||
| Operating margin | -153.1% | -240.9% | -38735.0% | – | – |
| Net margin | -148.4% | -226.8% | -37345.4% | – | – |
| Revenue growth, year over year | +60.6% | +13,699.0% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 27, 2025 | Feb 20, 2024 | Feb 28, 2023 | Feb 24, 2022 |
| Cash and equivalents | $163.1M | $115.7M | $114.9M | $231.7M | $78.2M |
| Short-term investments | $133.9M | $208.1M | $165.0M | $240.1M | $426.2M |
| Accounts receivable | $82.4M | $69.3M | $151.0K | – | – |
| Inventory | $51.7M | $51.5M | $10.4M | – | – |
| Total current assets | $442.7M | $457.0M | $307.8M | $479.1M | $508.0M |
| Property, plant and equipment | $131.1M | $109.1M | $114.0M | $105.2M | $100.9M |
| Intangible assets | $279.3M | $282.4M | $229.3M | – | – |
| Total assets | $913.2M | $910.4M | $780.4M | $664.0M | $777.3M |
| Accounts payable | $22.2M | $27.5M | $33.1M | $26.6M | $27.4M |
| Total current liabilities | $138.4M | $122.3M | $110.3M | $91.5M | $89.2M |
| Total liabilities | $214.6M | $200.0M | $195.7M | $164.3M | $155.7M |
| Shareholders' equity | $698.6M | $710.4M | $584.6M | $499.6M | $621.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 27, 2025 | Feb 20, 2024 | Feb 28, 2023 | Feb 24, 2022 |
| Operating cash flow | -$302.4M | -$353.0M | -$361.8M | -$292.8M | -$227.9M |
| Capital expenditures | $33.8M | $11.1M | $22.3M | $20.4M | $37.6M |
| Free cash flow | -$336.2M | -$364.0M | -$384.1M | -$313.2M | -$265.5M |
| Depreciation and amortization | $12.9M | $12.0M | $11.6M | $9.31M | $3.11M |
| Stock-based compensation | $61.6M | $109.6M | $62.6M | $84.0M | $69.8M |
| Investing cash flow | $47.5M | -$96.4M | -$155.2M | $256.5M | $132.0K |
| Financing cash flow | $300.8M | $390.7M | $463.0M | $190.2M | $239.3M |
| Net change in cash | $47.0M | -$59.3M | -$56.8M | – | – |
| Ratio | |||||
| Stock-based compensation, % of revenue | 23.4% | 66.8% | 5267.0% | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 27, 2026 | 462.7M | +16.5% | SEC |
| Jul 29, 2026 | 453.0M | +25.2% | SEC |
| Apr 15, 2026 | 446.5M | +33.7% | SEC |
| Feb 13, 2026 | 412.0M | +25.6% | SEC |
| Oct 15, 2025 | 397.0M | +30.2% | SEC |
| Aug 1, 2025 | 361.9M | +19.2% | SEC |
| Apr 30, 2025 | 333.9M | +19.3% | SEC |
| Feb 21, 2025 | 327.9M | +17.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.